Clinical Trial

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients

Study acronym: DTIC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 29, 2021 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to see if the combination of the two cancer drugs, Dacarbazine (DTIC) and a low-dose of Proleukin (IL2), would provide a less toxic and more effective treatment for melanoma than currently available treatments for people with high-risk melanoma. Dacarbazine (DTIC) and Proleukin (IL2) are both FDA-approved drugs for the treatment of melanoma.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2007-11-01; most recent amendment 2021-10-22.
Status change: Recruiting → Active, Not Recruiting 2016-11-21
Trial Details
NCT Number NCT00553618
Lead Sponsor University of Louisville
Collaborators: James Graham Brown Cancer Center
Conditions Metastatic Melanoma
Enrollment 160 participants
Start Date 2007-08
Primary Completion 2025-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2021-10-29